Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes
Clinical trial NCT01593670 · COMPLETED
Trial details
- NCT number
- NCT01593670
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-03-01
- Primary completion
- 2018-10-23
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.